A Newer in Vitro Model for the Study of Development of in vitro resistance to penicillin in a novel isolate of Streptococcus tigurinus

Objectives: Streptococcus tigurinus is a new member of the Streptococcus mitis group. It causes various invasive infections. Its isolation from the oral cavity has been reported recently for the first time in our previous study. An attempt has been made to develop a novel in vitro model for the study of development of resistance to penicillin and to find out its effect on susceptibility pattern of other antimicrobial agents in an isolate of S. tigurinus. Materials and Methods: An in vitro model mimicking in vivo conditions was developed to induce resistance in S. tigurinus with MIC value of 0.12 µg/ml to penicillin by 10 serial passages by sequential exposure to increasing concentration of penicillin. Results: The in vitro manipulation of original strain of S. tigurinus resulted in an increase in MIC value to 8 µg/ml indicating development of resistance to penicillin and a major increase in MIC value of ampicillin from 0.25 to 16 µg/ml, and increase in MIC values of cefepime (0.12 to 0.25 µg/ml), erythromycin (0.12 to 0.25 µg/ml), azithromycin (0.5 to 1 µg/ml) and clarithromycin (0.25 to 0.5 µg/ml) indicating development of cross-resistance to these antimicrobial agents. Conclusion: Results indicate that exposure to increasing concentrations of penicillin can induce the development of resistance to penicillin and cross-resistance to other antimicrobial agents. As in vitro conditions are quite similar to in vivo situation, the results obtained are more appreciable than routine methods using artificial media. 

___

  • 1.Zbinden A, Mueller NJ, Tarr PE, et al. Streptococcus tigurinus, a novel member of the Streptococcus mitis group, causes invasive infections. J Clin Microbiol 2012; 50:2969-2973. 2.Zbinden A, Mueller NJ, Tarr PE, Spröer C, Keller PM, Bloemberg GV. Streptococcus tigurinus sp. nov., isolated from blood of patients with endocarditis, meningitis and spondylodiscitis. Int J Syst Evol Microbiol 2012; 62:2941-2945. 3.Dhotre SV, Mehetre GT, Dharne MS, Suryawanshi MS, Nagoba BS. Isolation of Streptococcus tigurinus - a novel member of the Streptococcus mitis group from a case of periodontitis. FEMS Microbiol Lett 2014;357:131 – 135. 4.Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891-894. 5.Farber BF, Eliopoulos GM, Ward JI, Ruoff KL, Syriopoulou V, Moellering RC Jr. Multiple resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother 1983; 24:702–705. 6.Pottumarthy S, Morris AJ. Detection of decreased penicillin susceptibility in viridans group streptococci. Pathol 1998; 30:188-191. 7.Jones RN, Wilson WR. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. Diagn Microbiol Infect Dis 1998; 31:453–459. 8.Nagoba BS, Suryawanshi NM, Wadher BJ, Selkar SP. Norfloxacin induced cross-resistance to fluoroquinolones and non-fluoroquinolone groups of antimicrobial agents in Pseudomonas aeruginosa. Bang J Med Sci 2016; 15:533-537. 9.Deshmukh SR, Nagoba BS, Wadher BJ, Tumane P. Norfloxacin induced cross-resistance to fluoroquinolones & structurally unrelated antimicrobial agents in coagulase negative staphylococci. Ind J Med Res 1997; 106:461-464. 10.Nagoba BS, Deshmukh SR, Wadher BJ, Gude UG, Gomashe AV, Tumane PM. Induction of resistance to ciprofloxacin & other fluoroquinolones in clinical & environmental isolates of Pseudomonas aeruginosa. Ind J Med Microbiol 1998; 16:29-30. 11.Prasad SV, Ballal M, Shivananda PG. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa. Ind J Pathol Microbiol 2007; 50:94-96. 12.Dhotre SV, Nagoba BS, Suryawanshi NM. Induction of in vitro resistance to penicillin in viridians group streptococci and its effect on susceptibility pattern of other antimicrobial agents. JKIMSU 2016;5: 101-106. 13.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI document M100-S23 Wayne PA: Clinical and Laboratory Standards Institute; 2013.